Canakinumab Injection

DRUG3 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Jeffrey Curtis, University of Leipzig

Conditions

AnemiaMyelodysplastic SyndromesPsoriatic ArthritisRheumatoid ArthritisSpondylarthritis

Phase 1

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Active, not recruitingNCT04798339

H. Lee Moffitt Cancer Center and Research InstituteMyelodysplastic Syndromes

Start: 2021-03-30End: 2026-07-31Updated: 2025-10-31

Phase 2

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

TerminatedNCT05237713

University of LeipzigAnemia, Myelodysplastic Syndromes

Start: 2022-04-26End: 2024-02-29Updated: 2024-05-06

Phase 4

COVID-19 VaccinE Response in Rheumatology Patients

CompletedNCT05080218

Jeffrey CurtisPsoriatic Arthritis, Rheumatoid Arthritis, Spondylarthritis

Start: 2021-11-15End: 2024-05-28Updated: 2025-05-02

Related Papers

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials

Communications Medicine2026-09-16

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Blood Advances2023-11-0736 citations